THE CLINICAL UTILITY OF 18F- FLUCICLOVINE PET/MRI IMAGING TWO YEARS FOLLOWING FOCAL CRYO-ABLATION (FCA) OF PROSTATE CANCER

Brief description of study

In this pilot study, we want to know if position emission tomography (PET) imaging with 18F Fluciclovine (Axumin) helps to identify recurrence of prostate cancer in men who have undergone focal cryo-ablation (FCA). PET imaging will use a radioactive drug (tracer) to make images of tissues in the body and how they are functioning. The PET tracker used in this study Axumin is investigational because we are testing its use in men who may/may not have suspected cancer recurrence or elevated prostate-specific antigen (PSA) levels. Your participation in this study involves one visit to have the Axumin PET/MRI.


Clinical Study Identifier: s19-00123
ClinicalTrials.gov Identifier: NCT04009083
Principal Investigator: Herbert Lepor.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.